Form D · Other Technology
Arcadia Biosciences, Inc.
Dallas, TX · CIK 0001469443
Offering snapshot reported Jun 26, 2026 · SEC filing
- Reported sold
- $4M Offering amount: $11.4M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 12, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2026 | Initial | $3,999,613 | No comparison | 5 | SEC filing |
| Jan 27, 2026 | Initial | $2,082,132 | No comparison | 3 | SEC filing |
| Feb 16, 2021 | Initial | $25,000,000 | No comparison | 26 | SEC filing |
| Apr 11, 2018 | Initial | $10,000,000 | No comparison | 2 | SEC filing |
| Apr 25, 2014 | Initial | $18,944,527 | No comparison | 8 | SEC filing |
| Nov 25, 2009 | Initial | $2,372,092 | No comparison | 6 | SEC filing |
| Aug 4, 2009 | Initial | $15,200,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $395K
- Finders' fees
- $0
- Form D file number
- 021-588846
Includes gross proceeds received from issuance of pre-funded warrants & preferred investment options. Offering also reflects the aggregate exercise price of pre-funded warrants, preferred investment options and placement agent investment options issued.
In addition to cash fee, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 271,845 shares of common stock at exercise price $1.2875 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co, LLC | 375 |
Source: Form D, filed Jun 26, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Albert D. Bolles | Director |
| Steven Brandwein | Director |
| Steve Brandwein | Executive |
| Deborah Carosella | Director |
| David Collier | Director |
| Kevin Comcowich | Director |
| Uday Garg | Director |
| Pam Haley | Executive |
| Rajendra Ketkar | Director, Executive |
| Lilian Shackelford Murray | Director |
| Matthew T Plavan | Director, Executive |
| Eric Ray | Director |
| James Reis | Director |
| Eric J. Rey | Director, Executive |
| Thomas J. Schaefer | Director, Executive |
| Rachel Sheinbein | Director |
| Darby Shupp | Director |
| Jonathan Thatcher | Director |
| Gregory D Waller | Director |
| Mark Wong | Director |
| Amy Yoder | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
5956 Sherry Lane Suite 2000
Dallas, TX, 75225
Dallas, TX, 75225